Can the O-Shot Help Women After Breast Cancer?
What Survivors Should Know

Breast cancer treatment can change many parts of your life, including areas that may not come up during routine follow-up appointments. You might finish chemotherapy, return to your usual activities, and receive reassuring updates about your health, yet still experience vaginal dryness, burning, discomfort during intimacy, or changes in urinary function. These symptoms can be frustrating, especially when you are trying to reconnect with your body and move forward after treatment. If this sounds familiar, you deserve to know that intimate health concerns are real medical concerns, not something you simply have to accept.

For some women, the search for relief leads to questions about the O-Shot®, a platelet-rich plasma (PRP) injection procedure offered for certain intimate wellness concerns. Because the procedure uses components derived from your own blood rather than adding estrogen, it may attract the attention of women who have had hormone-sensitive breast cancer or who remain on endocrine therapy. But an important question deserves a careful answer: can the O-Shot actually help women experiencing intimate symptoms after breast cancer treatment, and what do we know about its safety?

The research is promising enough to deserve attention, but it is not definitive. A small 2025 pilot study investigated PRP injections for genitourinary symptoms in breast cancer survivors and reported improvements in several symptom and quality-of-life measures. However, the study was uncontrolled, involved only 20 participants, and did not establish the long-term safety or effectiveness of the branded O-Shot protocol. Those limitations matter when making a decision about an elective medical procedure.

At O-Shot Miami, the conversation should begin with your symptoms, your medical history, and your priorities. Understanding the available evidence can help you ask better questions, compare treatment options, and decide what deserves further discussion with your gynecologist and oncology team.

Understanding Intimate Health Changes After Breast Cancer

Breast cancer treatment can affect more than the breast itself. Chemotherapy, ovarian suppression, and medications designed to reduce estrogen activity can influence vaginal tissue, sexual comfort, urinary function, and overall quality of life. Some changes appear during treatment, while others become more noticeable months or years later. Because these symptoms can develop gradually, you may not immediately connect them to your cancer treatment. Understanding that connection is often the first step toward finding appropriate relief.

Why breast cancer treatment can affect vaginal and urinary health

Estrogen helps maintain the thickness, elasticity, moisture, and resilience of vaginal and vulvar tissues. It also contributes to the health of the urinary tract. When estrogen levels fall, these tissues can become thinner, drier, and more sensitive to friction. Activities that once felt comfortable, such as exercising, wearing fitted clothing, undergoing a pelvic examination, or having sex, may suddenly become uncomfortable.

Breast cancer treatment can contribute to these changes in several ways. Chemotherapy may temporarily or permanently affect ovarian function, bringing on menopause earlier than expected. Ovarian suppression intentionally reduces ovarian hormone production, while aromatase inhibitors lower estrogen levels to help reduce the risk of recurrence in appropriate patients. Tamoxifen also changes estrogen signaling, although its effects differ from those of aromatase inhibitors. These treatments serve important cancer-related purposes, but their effects on intimate health can be challenging.

Symptoms vary from person to person. One woman may primarily experience vaginal dryness, while another may report burning, pain during penetration, reduced comfort during intimacy, urinary urgency, or recurrent urinary tract infections. Some women experience several symptoms simultaneously, and the severity may change over time.

The emotional impact deserves attention, too. Intimate discomfort can affect relationships, confidence, sleep, and a person's sense of connection with their body. You might feel relieved that cancer treatment is behind you while simultaneously grieving the loss of comfort or spontaneity you previously took for granted. Both experiences can be true.

You do not have to choose between appreciating your recovery and asking for help with its consequences. Tell your healthcare team what has changed, even if your last oncology appointment focused on other concerns. Sexual and urinary health are legitimate parts of survivorship care.

Recognizing genitourinary syndrome of menopause (GSM)

Clinicians often use the term genitourinary syndrome of menopause (GSM) to describe symptoms and tissue changes associated with reduced estrogen and other hormonal changes. GSM can affect the vulva, vagina, bladder, and urethra, creating a combination of genital, sexual, and urinary symptoms. It can occur after natural menopause, but it can also develop when cancer treatment suppresses ovarian function or reduces estrogen activity.

Common symptoms include vaginal dryness, irritation, burning, discomfort during sexual activity, and tenderness during a pelvic examination. Some women notice urinary urgency, increased frequency, or repeated urinary infections. Others describe a persistent feeling of irritation without being able to identify a specific trigger.

Although GSM is common, it should not be assumed to explain every symptom. Vaginal infections, vulvar skin conditions, pelvic floor muscle dysfunction, medication effects, and other medical conditions can produce similar discomfort. Pain may also involve several overlapping causes. For example, reduced vaginal lubrication may lead to painful intimacy, and repeated pain may contribute to involuntary pelvic floor muscle tightening. Treating only one part of that cycle may not provide enough relief.

A healthcare professional can review your symptoms, medical history, medications, and examination findings to help determine what is happening. Depending on your symptoms, testing may be appropriate to investigate infection or another underlying condition.

Seek medical assessment for unexplained vaginal bleeding, persistent or worsening pain, a new vulvar lesion, unusual discharge, or recurrent urinary symptoms. These concerns should not be attributed to menopause automatically or treated with an elective injection before an appropriate clinical evaluation. Once the underlying cause is understood, you and your clinician can discuss treatments that fit your health history, including your breast cancer diagnosis and any ongoing therapy.

What Is the O-Shot and How Does PRP Work?

The O-Shot is a procedure that uses platelet-rich plasma, commonly abbreviated as PRP, for selected intimate wellness concerns. PRP is prepared from a sample of the patient's own blood and contains a concentrated amount of platelets compared with ordinary blood plasma. Platelets release signaling molecules involved in the body's response to tissue injury and repair. Researchers have been investigating whether these biological properties might have a role in certain gynecologic and sexual health conditions.

At O-Shot Miami, the procedure involves preparing PRP from a blood sample and injecting it into selected intimate tissues after local numbing. The exact procedure, preparation method, injection sites, and treatment protocol can vary between practitioners and studies. Those differences are important because evidence from one PRP protocol does not automatically establish the effectiveness of every commercially offered version.

Understanding platelet-rich plasma injections

PRP treatment generally begins with drawing a small amount of blood. The sample is processed, commonly through centrifugation, to separate its components and concentrate platelets in a portion of plasma. The resulting preparation is then administered to selected areas according to the clinician's treatment plan.

Platelets contain signaling proteins and growth factors that participate in biological processes such as wound healing and tissue repair. This has led researchers to explore PRP in different areas of medicine, including orthopedics, dermatology, and regenerative medicine. However, the biological activity of platelets does not guarantee that an injection will produce a clinically meaningful improvement in every tissue or condition.

For intimate health, the proposed rationale is that PRP may influence local tissue responses and potentially improve certain symptoms. Researchers are examining whether it can help women experiencing vaginal dryness, pain during intimacy, and other symptoms associated with genitourinary syndrome of menopause. The quality and quantity of evidence vary by condition, and much more research is needed before PRP can be considered an established treatment for breast cancer survivors.

It is particularly important to distinguish a plausible mechanism from a demonstrated clinical benefit. A treatment may appear promising in laboratory research or a small clinical study yet fail to show a meaningful advantage in larger controlled trials. For that reason, claims about PRP should be based on the outcomes actually measured in relevant studies rather than broad promises about regeneration or rejuvenation.

Before considering the O-Shot, ask which symptoms the proposed treatment is intended to address, what evidence supports that specific use, and what alternatives are available. Understanding the limits of the evidence is part of making an informed medical decision.

Why hormone-free treatments may interest breast cancer survivors

For women with a history of breast cancer, the possibility of a treatment that does not add estrogen can be appealing. This is particularly understandable for survivors whose tumors were hormone receptor-positive or who continue to take endocrine therapy. Some may worry that hormonal treatment could interfere with their cancer care, while others have received conflicting information about what is safe.

The O-Shot uses PRP derived from the patient's own blood rather than administering estrogen as its active ingredient. That distinction may be relevant when discussing treatment preferences, but it does not establish that PRP is effective or that its long-term safety has been demonstrated in this population.

Hormone-free does not automatically mean risk-free. Any injection procedure can have potential complications, and the long-term effects of PRP in breast cancer survivors remain insufficiently studied. Using a patient's own blood may reduce certain compatibility concerns, but it cannot answer every question about the effects of treatment on local tissues or long-term cancer outcomes.

It is also important to remember that not every symptom requires a hormonal or injection-based intervention. Lubricants, vaginal moisturizers, pelvic floor physical therapy, and treatment for an underlying infection or skin condition may offer relief, depending on the cause. Some women benefit from a combination of approaches rather than a single procedure.

The most useful question is not simply whether a treatment contains hormones. It is whether the treatment is appropriate for your diagnosis, has sufficient evidence for your symptoms, offers a reasonable balance of benefits and risks, and fits with your overall cancer survivorship plan.

What Does Research Say About the O-Shot After Breast Cancer?

Interest in PRP for breast cancer survivors has increased as researchers look for additional ways to manage the intimate health effects of cancer treatment. This is an important area of investigation because survivors may experience persistent symptoms while navigating concerns about conventional hormonal therapies. However, the evidence needs to be interpreted carefully, especially when a small study is used to inform decisions about a branded procedure.

Findings from the 2025 PRP pilot study

A prospective pilot study published in Obstetrics & Gynecology in 2025 (Chen AH et al.) investigated PRP treatment for genitourinary syndrome of menopause in breast cancer survivors. The study included 20 women previously treated for stage 0–III breast cancer who received one PRP treatment for vaginal dryness, with or without pain during intimacy.

Most participants had hormone receptor-positive disease, and some were taking aromatase inhibitors. The researchers assessed symptoms and quality-of-life measures over a six-month follow-up period. They reported improvements in several measures after treatment, providing preliminary evidence that PRP may warrant further investigation for selected symptoms in this population.

The study also documented short-term effects following treatment, including spotting, irritation, discharge, burning, cramping, and mild pain. The researchers reported no serious adverse events during the study period. These observations provide useful initial information about tolerability, but a sample of 20 participants is far too small to identify uncommon complications reliably or establish long-term safety.

The study is relevant because it directly examined breast cancer survivors rather than assuming findings from a general menopause population would apply equally to them. Women who have undergone cancer treatment may have distinct medical histories, ongoing medication requirements, and concerns about the consequences of elective treatment.

Still, the findings should be understood as preliminary. The study was not a randomized, placebo-controlled trial, and it did not establish that the branded O-Shot protocol offered by an individual clinic produces the same results. Differences in PRP preparation, injection technique, treatment sites, and patient selection can affect how closely the results of one study apply to another setting. The study's findings may justify further research and informed clinical discussion. They do not justify promising that PRP will relieve symptoms, restore sexual function, or prevent future health problems.

Understanding the limitations of current evidence

One of the most important limitations of the 2025 study is its lack of a comparison group. When participants report improvement after treatment, researchers cannot determine with confidence how much of that change resulted from the intervention itself. Symptoms may fluctuate naturally, participants may change other aspects of their care, and expectations can influence subjective assessments.

A controlled study can help separate these possibilities. Randomized trials that compare PRP with a suitable control, use clearly defined outcomes, and follow participants for longer periods would provide stronger evidence about effectiveness. Larger studies could also help researchers identify which patients are most likely to benefit and whether particular symptoms respond better than others.

Another limitation is the small sample size. Twenty participants cannot represent the full range of breast cancer diagnoses, treatments, medical histories, and symptom patterns encountered in clinical practice. A result observed in a small group may not apply to women with different cancer characteristics or ongoing treatment requirements.

The six-month follow-up period also leaves important questions unanswered. It cannot establish whether any reported improvement persists for years, whether repeated treatments are necessary, or whether uncommon or delayed adverse effects occur. It also cannot determine whether PRP affects breast cancer recurrence risk.

Finally, PRP is not a single standardized intervention across all settings. Preparation systems, platelet concentrations, injection sites, and administration techniques can differ. A study of one protocol should not be treated as direct proof that every procedure marketed as an O-Shot is equally effective or safe.

The appropriate takeaway is balanced: early research offers a reason to investigate PRP further, but not enough evidence to establish the O-Shot as a standard treatment for intimate symptoms after breast cancer. Women considering the procedure should understand what the research has shown, what remains unknown, and which alternatives have a more established role in care.

Is the O-Shot Safe for Breast Cancer Survivors?

Safety is one of the most important questions to discuss before an elective procedure, particularly when you have a history of breast cancer. A clinician should consider not only the injection itself but also your cancer diagnosis, current medications, blood counts when relevant, medical conditions, and the symptoms you want to address. The available evidence does not support a blanket claim that the O-Shot is safe for every survivor, nor does it establish that every survivor must automatically avoid it.

Cancer recurrence concerns and unanswered questions

Women who have experienced breast cancer understandably want to minimize anything that could compromise their recovery or future health. If you had hormone receptor-positive cancer, you may be especially cautious about treatments intended to influence intimate tissues. Those concerns deserve a direct, evidence-based discussion rather than reassurance based solely on the fact that PRP comes from your own blood.

The 2025 pilot study provides early information about short-term outcomes, but it was not designed or large enough to determine whether PRP affects breast cancer recurrence. The absence of serious adverse events in a small study over six months cannot establish that a procedure has no long-term risks. Equally, the lack of definitive long-term data does not prove that the procedure causes recurrence.

It is important to separate these questions. Researchers can investigate whether a procedure improves dryness or pain, whether it causes local complications, and whether it has any relationship to long-term cancer outcomes. Each question requires appropriate evidence, and improvement in one area does not automatically answer the others.

The fact that PRP does not contain added estrogen is relevant to understanding the procedure, but it is not sufficient to establish oncologic safety. Your oncology team can help interpret your individual circumstances, including your tumor characteristics, treatment history, and any ongoing endocrine therapy.

Until stronger evidence is available, PRP should be discussed as an elective intervention with uncertain long-term outcomes in breast cancer survivors. It should not be presented as a proven method of preventing cancer recurrence, treating cancer, or eliminating the risks associated with other treatments.

Why coordination with your oncology team matters

Your oncologist understands details of your cancer history that may not be obvious during a general wellness consultation. These may include hormone receptor status, the purpose and expected duration of endocrine therapy, prior treatment complications, and your individual recurrence-risk considerations. Sharing those details can help ensure that a decision about intimate health fits into your broader survivorship plan.

Coordination becomes especially important if you are actively receiving cancer treatment, taking an aromatase inhibitor or tamoxifen, experiencing unexplained bleeding, or managing another medical condition that could affect procedural suitability. Your gynecologist can evaluate local symptoms, while your oncology team can help address questions related to cancer treatment and survivorship.

Before scheduling an elective PRP procedure, ask your clinicians to clarify what is known, what is uncertain, and whether another treatment should be tried first. If your symptoms have not been evaluated, diagnosis should take priority over an injection.

A good medical consultation should also discuss possible side effects, aftercare, costs, the likelihood that further treatment may be needed, and what happens if the procedure does not help. You should have enough information to make a decision without feeling pressured to proceed.

At O-Shot Miami, the appropriate next step is a discussion of your symptoms and medical history, with oncology coordination when indicated. If PRP is not suitable or the evidence does not support it for your particular concern, an alternative treatment plan may be more appropriate.

Treatment Options for Vaginal Dryness and Intimate Discomfort

The O-Shot is not the only option for women experiencing intimate symptoms after breast cancer treatment. In many cases, the most helpful approach begins with a medical evaluation and treatments that have an established place in managing dryness, friction, pelvic floor dysfunction, or other identified causes. The right choice depends on your symptoms, your medical history, your preferences, and the treatments you have already tried.

Nonhormonal treatments and pelvic floor therapy

Nonhormonal vaginal moisturizers are commonly recommended as an initial option for persistent dryness. They are designed to provide ongoing moisture and may be used regularly according to product instructions. Lubricants, meanwhile, can reduce friction during sexual activity or other situations in which vaginal tissue feels uncomfortable. These products serve different purposes, and some women find that using both is more helpful than relying on either one alone.

Product choice can matter. Fragrance-free formulations intended for vaginal use may be preferable for people who experience irritation. If a product causes burning or discomfort, stop using it and ask your clinician about alternatives. A healthcare professional can help you compare formulations and develop a routine that suits your symptoms.

Pelvic floor physical therapy may help when pelvic muscle tension, guarding, or coordination problems contribute to pain. Persistent discomfort can sometimes create a cycle in which the body involuntarily tightens the pelvic floor in anticipation of pain, making intimacy even more uncomfortable. A trained pelvic floor therapist can assess muscle function and, where appropriate, use individualized exercises and other techniques to improve relaxation, coordination, and comfort.

Other treatments may be needed when symptoms have a different cause. Infections, dermatologic conditions, and certain urinary problems require condition-specific assessment and management. Treating these issues directly is more appropriate than assuming all post-treatment discomfort stems from low estrogen.

The American College of Obstetricians and Gynecologists (ACOG) recommends nonhormonal approaches as first-line treatment for urogenital symptoms in individuals with a history of estrogen-dependent breast cancer. This guidance provides a useful starting point, although treatment should still be tailored to the individual.

If nonhormonal measures do not provide sufficient relief, that does not mean you have run out of options. It means the next step is a conversation about your diagnosis, the strength of the evidence for different treatments, and the benefits and risks that matter most to you.

When to discuss vaginal estrogen with your care team

Some women with a history of breast cancer continue to experience significant symptoms despite using moisturizers and lubricants. In these circumstances, it may be appropriate to discuss additional treatment options with a gynecologist and oncologist.

ACOG states that low-dose vaginal estrogen may be considered for some individuals with a history of estrogen-dependent breast cancer after nonhormonal treatments have been inadequate and the potential benefits and risks have been discussed. For people taking tamoxifen, the decision can be considered through shared decision-making. For those taking aromatase inhibitors, ACOG recommends a shared decision involving the patient, gynecologist, and oncologist.

These distinctions are important because treatments that affect hormone levels can have different implications depending on the patient's diagnosis and ongoing therapy. Low-dose vaginal estrogen is not the same as systemic menopausal hormone therapy, and the two should not be treated as interchangeable. At the same time, local treatment should not be described as universally safe for every survivor without considering individual circumstances.

Your clinician can explain the available formulations, expected benefits, uncertainties, and alternatives. If a treatment is being considered, the discussion should include your symptom severity, previous treatment response, current medications, and the goals of your cancer care.

The purpose of shared decision-making is not to push you toward or away from one option. It is to help you understand the trade-offs and choose a plan that reflects your medical situation and priorities.

The National Cancer Institute also recognizes that cancer and its treatment can affect women's sexual health and that supportive care is available. You can raise these concerns during survivorship visits, even if your primary cancer treatment ended years ago.

Who Might Consider an O-Shot Consultation?

An O-Shot consultation may be worth discussing for a woman who continues to experience intimate symptoms and wants to understand whether PRP has a potential role in her care. However, being interested in the procedure does not automatically mean it is medically appropriate. The first step is identifying the problem that needs treatment and determining whether the available evidence supports the proposed approach. Learn more in our detailed guide on who is a good candidate for the O-Shot.

Your medical history is an important part of that assessment. The clinician may need to understand your original breast cancer diagnosis, whether you have completed treatment, whether you are taking tamoxifen or an aromatase inhibitor, and whether you have experienced complications that could affect procedural planning. Your current symptoms, previous treatments, and other medical conditions also matter.

Blood-related factors may be relevant because PRP is prepared from a blood sample. Depending on your circumstances, a clinician may need to consider blood counts, bleeding risks, medications, or other conditions that affect your suitability for an injection. Active infection, unexplained vaginal bleeding, or an undiagnosed lesion should be evaluated before an elective procedure is considered.

Your expectations are equally important. If your primary concern is dryness, ask whether the procedure has been shown to improve that specific symptom and how its evidence compares with established treatments. If your main concern is pain, discuss whether the pain could arise from pelvic floor dysfunction, skin irritation, infection, or another cause that would require a different approach.

It is also reasonable to ask what a meaningful improvement would look like for you. Perhaps you want to tolerate a pelvic examination more comfortably, experience less burning during everyday activities, or feel less pain during intimacy. Clear goals can make it easier to assess whether a treatment is helping and whether the potential benefits justify the cost and uncertainty.

An O-Shot consultation should provide space to discuss these questions without an obligation to proceed. If the evidence is insufficient for your situation, another option may offer a better-established path toward relief. If PRP remains under consideration, the decision should be made with realistic expectations and appropriate coordination with your healthcare team.

What to Expect at an O-Shot Miami Consultation

A consultation at O-Shot Miami with Dr. Nina Gupta, MD begins with your concerns rather than with an assumption that a particular procedure is the answer. Intimate symptoms can be difficult to discuss, especially when they have developed alongside a breast cancer diagnosis and treatment. A respectful conversation gives you an opportunity to describe what has changed, how long symptoms have been present, and how they affect your daily life.

Your medical history is an essential part of the discussion. Bring a current list of medications and information about your breast cancer treatment, including any ongoing endocrine therapy. If you have received specific guidance from your oncologist about vaginal or sexual health treatments, sharing that information can help the clinician understand the recommendations already in place.

The consultation may also involve discussing whether further evaluation is needed before considering PRP. If symptoms suggest an infection, a vulvar skin condition, unexplained bleeding, or another medical issue, the appropriate next step may be an examination or additional testing rather than an elective procedure. Identifying the cause can prevent unnecessary treatment and help you choose an approach that addresses the actual problem.

If PRP is still being considered after the initial review, ask for a clear explanation of the proposed procedure, including the preparation method, injection sites, expected recovery, possible side effects, and evidence supporting its use for your specific symptoms. You should also understand that results cannot be guaranteed and that the long-term safety evidence in breast cancer survivors remains limited.

Cost and follow-up are practical considerations, too. The O-Shot treatment at O-Shot Miami is transparently priced at $1,500. Read our guide on how much the O-Shot costs for full fee details. Ask what the consultation and procedure include, whether repeat treatments might be proposed, and how your progress would be assessed. An informed decision should account for both the medical uncertainties and the financial commitment.

O-Shot Miami is located in Miami (Aventura) and offers a discreet, comfortable medical setting in which you can discuss intimate wellness concerns and available options. You can explore O-Shot candidacy or contact O-Shot Miami to request a consultation. A consultation is an opportunity to ask questions and review your options, not a commitment to receive treatment.

Questions to Ask Before Choosing PRP Treatment

When you are considering an elective procedure after breast cancer, asking detailed questions is an important part of protecting your health and making a confident decision. You do not need to know all the medical terminology before attending a consultation. You simply need enough information to understand what the procedure is intended to do, how strong the supporting evidence is, and what alternatives deserve consideration.

• Which symptom is the treatment designed to address? Vaginal dryness, pain during intimacy, urinary urgency, and pelvic floor dysfunction have distinct causes. A procedure investigated for one symptom should not be assumed to treat the others.
• What does the scientific evidence show? Was the study performed on breast cancer survivors? Did it evaluate the exact PRP preparation and injection technique being recommended? Was there a comparison control group, and how long were participants monitored?
• What are the known side effects and oncologic safety questions? Which short-term side effects occurred? What remains uncertain regarding cancer recurrence risk? How does this procedure align with your ongoing endocrine therapy?
• What established alternatives should be considered first? Would specialized moisturizers, lubricants, pelvic floor rehabilitation, or medical therapies be appropriate first-line steps?
• What are the financial costs and follow-up plans? How will treatment efficacy be evaluated? What are the expenses if additional sessions are recommended?

A qualified clinician should be willing to answer these questions clearly and acknowledge uncertainty when the evidence is incomplete. Be cautious of guarantees, claims that a treatment is entirely risk-free because it uses your own blood, or suggestions that you should disregard your oncology team's guidance.

The goal is not to find a procedure at any cost. It is to find a treatment plan that addresses your symptoms, respects your medical history, and gives you the clearest possible understanding of potential benefits and risks.

Conclusion: Making an Informed Decision About Intimate Wellness

Breast cancer survivorship can bring a mixture of relief, gratitude, uncertainty, and unexpected physical changes. For some women, vaginal dryness, burning, pain during intimacy, or urinary symptoms become an ongoing part of life after treatment. These concerns deserve thoughtful medical attention, regardless of how long it has been since the original diagnosis.

The O-Shot, which uses platelet-rich plasma prepared from your own blood, is one procedure being explored for intimate wellness concerns. A small 2025 pilot study in breast cancer survivors reported improvements in several symptom and quality-of-life measures after PRP treatment. Those findings are encouraging enough to support further investigation, but they do not establish that the branded O-Shot is a proven treatment for breast cancer survivors or that its long-term cancer safety is known.

A sensible approach begins with a diagnosis. Nonhormonal vaginal moisturizers, lubricants, pelvic floor physical therapy, and treatment for any underlying condition may help, depending on what is causing your symptoms. If those options are insufficient, your gynecologist and oncology team can discuss whether other treatments, including selected hormonal options, may be appropriate for your circumstances.

If you are considering PRP, make sure you understand the evidence, possible side effects, costs, alternatives, and unanswered questions. Share your cancer treatment history and current medications, and involve your oncology team when appropriate. No elective procedure should replace necessary cancer follow-up or an evaluation of new or unexplained symptoms.

At O-Shot Miami, Dr. Nina Gupta can discuss your intimate health concerns and the options available for your situation. The purpose of that conversation is to help you make an informed decision, not to promise a particular result. You deserve care that takes both your recovery and your quality of life seriously.

Medical References

1. Chen AH, et al. Platelet-Rich Plasma for Genitourinary Syndrome of Menopause in Breast Cancer Survivors. Obstetrics & Gynecology. 2025;146:728–736. Prospective, uncontrolled pilot study. PubMed: 40966714
2. American College of Obstetricians and Gynecologists (ACOG). Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer. Clinical Consensus, 2021.
3. National Cancer Institute. Sexual Health Issues in Women with Cancer.
4. The Menopause Society. Genitourinary Syndrome of Menopause (GSM).